Research conducted at the Lady Davis Institute provides proof of concept that an existing drug holds promise for reversing loss of memory and brain lesions associated with Alzheimer disease.
New research conducted at the Lady Davis Institute (LDI) at the Jewish General Hospital reveals that a novel drug reverses memory deficits and stops Alzheimer disease pathology (AD) in an animal model. Importantly, this drug has already proven to be non-toxic for humans in a clinical setting and could, therefore, be brought quickly to trials in humans against AD. These findings are published today in Nature Communications.
For years, Dr. Andréa LeBlanc, Senior Investigator at the LDI and Professor of Neurology and Neurosurgery at McGill University, has strived to identify early neurodegenerative events responsible for age-related memory loss. Her team discovered that the Caspase-6 enzyme is highly activated in Alzheimer disease brain lesions and associated with loss of memory. She, therefore, pursued the hypothesis that stopping Caspase-6 might provide relief from memory loss and stop progressive dementia. Since there are no specific Caspase-6 inhibitors, the LeBlanc team moved upstream, ultimately discovering that Caspase-1 was responsible for activating Caspase-6.
“This was a significant revelation because Caspase-1 inhibitors had been developed for treating inflammatory diseases,” explains Dr. LeBlanc. “Thus, we decided to test the effects of a particular Caspase-1 inhibitor, called VX-765, against memory loss and brain pathologies in a mouse model of Alzheimer disease.”
The work, first authored by Dr. Joseph Flores, a research associate in the LeBlanc lab, showed that VX-765 has an unprecedented beneficial effect in Alzheimer mice. The drug rapidly reverses memory loss, eliminates inflammation, and stops Alzheimer’s prototypical amyloid peptide accumulation in the mice brains. In addition to being safe for humans at relatively high doses for extended periods of time, it is capable of reaching the brain, a significant challenge in the development of drugs against disorders of the brain.
While Dr. LeBlanc cautions that there is a considerable bridge to cross between the mouse brain and that of a human, she believes that since her work has first identified the Caspase-1/Caspase-6 neurodegenerative pathway in human neurons and in human Alzheimer brains, there is a chance that this drug will work just as well in humans as it did in mice. Nevertheless, a clinical trial is needed to determine whether the drug will be beneficial against Alzheimer disease in humans.
Presently, there are no efficient treatments to significantly treat Alzheimer disease, the major affliction in a group of dementias that affect 47.5 million individuals worldwide.
The Latest on: Alzheimer’s
via Google News
The Latest on: Alzheimer’s
- Obituary: Bernice Betty Ritter on February 18, 2019 at 3:05 pm
Bill passed away in 2000 and Bernice moved back to Great Falls until Alzheimers forced her to go into assisted living. To read the complete obituary and share condolences, visit the Schnider ... […]
- Alzheimers/dementia caregivers support group to meet on February 18, 2019 at 6:59 am
OWATONNA — The next Afternoon Support Group for Caregivers assisting people with Alzheimer’s or another dementia will be Tuesday, Feb. 19 from 2:30-3:30 p.m. at the Owatonna Public Library, 105 N Elm ... […]
- Oregon Researchers Seeking Patients With Early Signs Of Alzheimer's on February 18, 2019 at 5:54 am
Dr. William Burke goes over a PET brain scan Tuesday, Aug. 14, 2018, at Banner Alzheimers Institute in Phoenix. Matt York Originally published on February 17, 2019 11:53 am A Portland memory center is ... […]
- Whangārei man completes North Island trek, reaches fundraising goal for Alzheimers Northland on February 15, 2019 at 12:00 pm
The feat of walking the entire length of the North Island for charity is still sinking in for Whangārei man Dean Raynel. The community corrections probation officer set off from Cape Reinga on Decembe... […]
- Alzheimer's study emphasize lowering blood pressure and good dental health to reduce risk on February 14, 2019 at 2:41 pm
Eighty-nine thousand people in South Carolina, alone, are living with Alzheimers and over the next six years that number is expected to jump by 35 percent, according to the Alzheimer's Association. Al... […]
- Chili cookoff event benefiting Alzheimers research set for Saturday on February 13, 2019 at 2:31 pm
The biggest local chili party of the year is coming up this weekend in Fayetteville. The 14th annual Chilirhea chili cook-off is set for Saturday, Feb. 16 at the Washington County Fairgrounds. The eve... […]
- Researchers identify novel molecular mechanism involved in Alzheimer's on February 12, 2019 at 11:47 pm
The findings are published in the current issue of the Journal of Clinical Investigation. Alzheimers is such a devastating disease and currently there is no cure or effective therapy, said Tao Ma, Ph. ... […]
- Alzheimer's Disease Biomarkers Market to Be at Forefront by 2026 on February 11, 2019 at 10:26 pm
Symptoms of the disease are memory loss and mild confusion, often termed as dementia. View Report: https://www.transparencymarketresearch.com/alzheimers-disease-biomarkers-market.html These symptoms a... […]
- Weekly Wellness: Advice for Alzheimers Caregivers on February 11, 2019 at 11:06 am
If you have a loved one with Alzheimer’s (or dementia), you know how challenging it can be. The stress can be overwhelming for everyone involved. What we do know is that trying to keep our loved ones ... […]
via Bing News